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BACKGROUND: Locally advanced breast cancers are more prevalent in underdeveloped countries. Targeted therapy
has been improved to identify hallmarks that are specific to these subtypes of tumors.
OBJECTIVES: We aimed to prospectively assess the expression of Hypoxia inducible factor-1 a and vascular
endothelial growth factor-C in locally advanced breast cancer patients.
METHODS: Thirty women underwent incisional biopsies for the histopathological diagnosis of breast carcinoma and
participated in neoadjuvant chemotherapy. The association of Hypoxia inducible factor-1 a and vascular endothelial
growth factor-C with age, tumor size, histological grade, clinical staging, hormonal and axillary status, clinical and
pathological response after neoadjuvant chemotherapy, expression of estrogen and progesterone receptors, and
the presence of c-erbB-2 antigen was studied.
RESULTS: Hypoxia inducible factor-1 a expression and Vascular endothelial growth factor-C expression were
observed in 66.7% and 63.3% of all patients, respectively, and were marginally associated with each other (p=0.06).
Among the studied variables, only positive axillary status was associated with the presence of HIF-1a (p=0.02).
Complete pathological response was significantly associated (p=0.04) with the expression of vascular endothelial
growth factor-C prior to neoadjuvant chemotherapy.
CONCLUSION: We concluded that Hypoxia inducible factor-1 a was associated with a poor prognosis and that
vascular endothelial growth factor-C could be used as a predictive factor in locally advanced breast cancer patients
with complete pathological response after neoadjuvant chemotherapy.
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INTRODUCTION
Breast cancer is one of the main causes of death in
occidental women. Statistics have indicated that the
frequency of breast cancer has recently increased in
developed and developing countries.1 In the USA, 192,370
women were diagnosed with breast cancer in 2009, and
40,170 deaths occurred.1
Randomized trials performed between 1976 and 1990
have shown that early detection through mammographic
examination reduced mortality from breast cancer by 25% in
women between 50 and 69 years old.2 Although the
government provides incentives for mammography,
approximately 10% of breast tumors are diagnosed as
locally advanced tumors (LABC), which have a greater risk
of metastasis and a reserved prognosis.3 Unlike the USA
and European countries, where the incidence of breast
cancer is increasing and mortality is decreasing, the
mortality rate of breast cancer in Brazil is high due to the
relatively high percentage (50%) of LABC cases.4
Surgery is not the primary recommended method of
treatment for LABC. Neoadjuvant therapy reduces the
tumor’s primary volume and transforms inoperable breasts
into operable ones, increasing the conservative surgery rate.
By identifying patients who present an optimal response to
certain treatments, mechanisms that support tumor growth
can be discovered, and novel targeted therapies can be
developed. All solid tumors require a microenvironment
that promotes angiogenesis, which either maintains tumor
viability and its growth or contributes to the spread of the
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disease.5 Vascular endothelial growth factors (VEGFs)
constitute a family of potent angiogenic peptides that act
on the development of hematopoietic stem cells, remodel
the extracellular matrix (ECM) and regenerate inflammatory
cytokines. The VEGF family is classified into various
subtypes (A to D). VEGF-C and -D are produced by
tumor-associated macrophages (TAMs), which express
VEGFR-3 (the VEGF-3 receptor). Microvascular lymphatic
density and the abovementioned hallmarks promote the
lymphatic dissemination of breast tumor cells, which is
directly related to the axillary status and prognosis of the
patient.6
Another important mechanism that leads to angiogenesis
is tissue hypoxia. Hypoxia is present in many solid tumors
and is caused by abnormal neoplastic vascularization and
rapid cell production, which results in apoptosis and areas
of necrosis.7 Based on the results of several studies on the
clinical applicability of hallmarks as a targeted therapy,
biochemical hallmarks produced in hypoxic environments
are related to several cancers (especially breast tumors) and
have been considered as prognostic factors for highly
undifferentiated tumors.8,9 However, it is not known if
hypoxia is the cause or the effect of the formation of
aggressive tumors.
Hypoxia inducible factor-1 (HIF-1) is a heterodimeric
nuclear transcription factor that is divided into two subunits
(alpha [a] and beta [b]). Subtype 1a is overexpressed in
breast tumors 10 and is of functional importance. Under
normoxic conditions, HIF-1a is recognized by von Hippel-
Lindau (pVHL) proteins, hydroxylated by proline hydro-
xylases (PHDs) and factor-inhibiting HIF (FIH), and is
ubiquitinated by the proteasome.10 However, the PHD and
FIH levels is low during hypoxia. Thus, HIF-1 migrates from
the cytoplasm to the nucleus and binds to hypoxia response
elements (HREs), leading to the expression of targeted
genes.10 Specifically, increases in the activation of genes that
control glucose transportation, glycolysis, growth factor
production, high-energy phosphate metabolism, erythropoi-
esis, heme metabolism, iron transport and nitric oxide
synthesis are observed.
The role of HIF-1 in breast carcinogenesis is related to the
induction of VEGF transcription, which leads to a greater
rate of tumor angiogenesis.11,12 In preclinical studies with
metastatic patients, monoclonal antibodies against VEGF,
such as bevacizumab, were used to control tumors.13 HIF-1a
can also be overactivated by vascular growth factors, such
as PDGF (platelet-derived growth factor), EGF (epidermal
growth factor), FGF-2 (fibroblast growth factor type 2), TGF-
1b (transforming growth factor type 1 beta), IGF (insulin
growth factor) and cytokines, such as TNF-a (tumor necrosis
factor alpha) and interleukin (IL) 1b. Overactivation occurs
through two important signaling pathways, the RAS/MEK/
MAPK and PI3K/AKt/mTOR cascades.10
Several investigations on the prognostic value of HIF-1a
in breast cancer have been conducted. Schindl et al.14
showed that HIF-1a overexpression was associated with
poor overall survival rates in LABC patients. However, Bos
et al.5 identified an association between HIF-1a expression
and survival in negative lymph node patients. In our
previous study, significant differences between the serum
levels of HIF-1a and VEGF were not observed before or after
neoadjuvant chemotherapy (NACT).16 Studies on the
modifications of the immunohistochemical and serum
expression of HIF-1a and VEGF after NACT are scarce.
Although VEGF is a classical prognostic and predictive
factor for breast cancer, the relationship between VEGF and
HIF-1a has not yet been established. Therefore, we analyzed
the expression of HIF-1a and VEGF in LABC patients with
the goal of identifying associations between the expression
of these two genes and other prognostic factors.
METHODS AND MATERIALS
Patients
The present investigation was a prospective study.
Consecutive sampling was conducted in the outpatient
clinic of the Breast Division of the Hospital das Clı´nicas,
Ribeira˜o Preto School of Medicine – University of Sa˜o Paulo
(HC-FMRP-USP) from March to November of 2009, and 30
locally advanced breast cancer patients were evaluated. All
the patients signed informed consent forms before partici-
pating in the study. The Ethics Research Committee of HC-
FMRP-USP approved this research.
The following inclusion criteria were applied: no previous
treatment for breast cancer, between 25 and 80 years of age,
and with an indication for NACT (the presence of stage II
and III tumors, where the tumor volume/breast volume
ratio did not allow for conservative surgery), as assessed by
our clinic. The exclusion criteria were as follows: patients
with a reduced Karnofsky performance status scale,
previous malignant neoplasm, pregnancy, and confirmed
metastatic disease.
Prior to chemotherapy, an incisional biopsy was per-
formed for histopathological diagnosis. During the proce-
dure, a 1-cm3 tissue block was removed and stored in
Tissue-Tek O.C.T. (Qiagen, USA). Except for one patient,
who was diagnosed with lobular carcinoma, all of the
patients were diagnosed with invasive ductal carcinoma
(WHO criteria).
Baseline characteristics
The following clinical variables were studied: age (years),
tumor size (in centimeters), histological grade,17 clinical
staging,18 and menopausal status (pre- and post-meno-
pause). Clinical and pathologic responses were evaluated in
all of the patients. The clinical assessment of tumor features
was based on RECIST criteria;19 however, the following
modified definitions were employed: complete response: no
existence of clinical disease; partial response: less than a
50% reduction in lesion measurements; minor response/
progression: less than 25% reduction or an increase in tumor
volume. Pathologic response was determined according to
an identical rubric.
The histopathological results of lymph node dissection
after NACT were considered when the axilla was clinically
negative. Alternatively, if the physical examination indi-
cated that the cancer had metastasized to the lymph nodes,
NACT was immediately conducted. NACT consisted of
docetaxel (75 mg/m2) and epirubicin (60 mg/m2) on the
first day, preceded by hydration with isotonic fluid,
dexamethasone and antiemetic (ondansentron). The proce-
dure was repeated every three weeks.
The mean/standard deviation and median age of all 30
patients were 51.96¡12.65 and 52 years, respectively. Thus,
most (66.7%) of the patients were more than 50 years old.
The mean/standard deviation and median size of breast
lumps were 5.85¡4.19 (range 2.7 to 25) and 5 cm,
respectively. Table 1 shows the baseline features of the
HIF-1a and VEGF-C were prevalent in locally advanced breast cancer patients
Brito LGO et al.
CLINICS 2011;66(8):1313-1319
1314
patients. Most of the women were postmenopausal and
possessed aggressive histological tumors in advanced
clinical stages (IIIA: 33%). In total, 54.2% displayed
complete clinical response, and 28.6% displayed complete
pathological response. Half of the patients possessed a
positive axillary status.
Immunohistochemistry and quantification of ER,
PR, C-erbB-2, VEGF-C and HIF-1-a
Tissue sections with a diameter of 4 micrometers were
obtained with a cryostat, and immunohistochemistry was
performed according to the avidin-biotin-peroxidase com-
plex (ABC) method. The tissue sections were fixed in 100%
acetone for 10 minutes at 20 C˚. Endogenous peroxidase
activity was blocked by incubating the slides in a solution of
hydrogen peroxide (0.3%) and PBS for 30 minutes. After
antigen retrieval, the sections were cooled for 20 minutes
and then incubated with the primary antibody for two
hours at 37 C˚. The specimens were washed and incubated
for 45 minutes with biotinylated secondary antibodies.
When the incubation was complete, the signal was
amplified by the formation of an avidin-biotin complex
and was developed with diaminobenzidine and Mayer’s
hematoxylin counterstain (Zymed Laboratories Inc., CA,
USA).
HercepTest (Dako System) was employed to immunohis-
tochemically quantify the HER-2 antigen. A score of +3 (10%
of the tumor cells showed strong and complete nuclear
membrane staining) was considered positive for HER-2. The
test results were considered negative when membrane
staining did not occur or was absent in less than 10% of
the tumor cells.20 When intermediate tumors were identified
(2+), CISH (chromogenic in situ hybridization) was con-
ducted. Estrogen and progesterone receptor (ER and PR)
status was determined when nuclear staining was visua-
lized and was considered positive when more than 10% of
the cells were stained.21 Mouse MAb was applied to analyze
HIF-1a (Abcam Company), and quantification of darkly
stained epithelial nuclei was performed.22 Cytoplasmic
stainings were ignored, and the scoring rubric applied to
ER/PR was employed. An anti-VEGF-C antibody was used
(BD Biosciences) to analyze VEGF-C. To score VEGF-C
stains, the percentage of strongly stained tumor cells was
assessed.12 Staining was scored by three observers (L.G.O.B,
V.F.S, and H.R.C.M), who were blinded to the clinical
outcomes.
Statistical analysis
The intercooled Stata statistical package version 8.0 (Stata
Corporation, Texas, USA) was used to interpret the data. A
Fisher’s test was performed to assess the link between ER,
PR, c-erbB-2 and the presence or absence of HIF-1a and
VEGF-C. The mean, median and standard deviation of the
continuous variables were also calculated. A significance
level of 5% was used in two-tailed tests.
RESULTS
Table 2 displays the positivity/negativity ratio of the
immunohistochemical variables. Approximately 30% of all
patients were positive for c-erbB-2 antigen. HIF-1a expres-
sion was observed in 66.7% of the patients; however, the
number of patients with HIF-1a expression was reduced to
25.9% when only strong and diffuse staining was consid-
ered (Figure 1). VEGF-C was expressed in two-thirds of all
cases, primarily in the cytoplasm of tumor cells (Figure 2).
A trend between HIF-1a expression and age less than 50
years (p= 0.08) was observed, as was a statistically sig-
nificant association with positive axillary status (p= 0.02)
(Table 2). A marginally significant trend between elevated
HIF-1a levels and the following variables was also observed:
pre-menopausal women (p = 0.10), reduced pathologic
response (p= 0.12) and higher clinical response (p= 0.09).
A statistically significant association between HIF-1a
expression and immunohistochemical markers (ER, PR
and c-erbB-2) was not observed (Table 2).
When VEGF-C expression was correlated with other
variables, only the complete pathological response was
associated with it (p= 0.04). Histological grading, axillary
status, tumor size, age, menopausal status, ER, PR and c-
erbB-2 were not associated with VEGF-C. HIF-1a expression
was marginally associated with VEGF staining (p= 0.06).
DISCUSSION
The objectives of the present study were to assess the
expression of HIF-1a and VEGF-C in LABC patients,
Table 1 - Baseline characteristics of the studied patients
(Ribeira˜o Preto, Brazil, 2010).
Variables n %
Age (years)
,50 10 33.3
50+ 20 66.7
Tumor size (cm)
#5 15 50
5.1-10 13 43.3
.10 2 6.7
Menopausal status
Pre-menopause 14 46.7
Post-menopause 16 53.3
Histological subtype
Ductal 28 93.3
Lobular 2 6.7
Histological grade
I 3 10
II 16 53.3
III 11 36.7
Clinical staging (TNM)
IIA 4 13.3
IIB 4 13.3
IIIA 10 33.4
IIIB 7 23.3
IIIC 5 16.7
Estrogen receptor (ER)
Positive 19 63.3
Negative 11 36.7
Progesterone receptor
(PR)
Positive 14 46.7
Negative 16 53.3
c-erbB-2
Positive 10 33.3
Negative 20 66.7
HIF-1a
Positive 20 66.7
Negative 10 33.3
VEGF-C
Positive 19 63.3
Negative 11 36.7
Total 30 100.0
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determine possible prognostic and/or predictive functions,
and identify associations with clinical and immunohisto-
chemical markers.
The expression level of HIF-1a (66.7%) was similar to
those observed in other studies. For instance, Gruber23 and
Bos12 observed an expression rate of 56%, and Kronblad24
obtained an expression level of 67%. However, some
deviations were observed due to the diversity of cut-off
points used in the aforementioned studies.10 Subjectively, a
higher concentration of HIF-1a was detected in perinecrotic
areas, which likely corresponds to activation by hypoxia.
However, Vleugel et al.25 showed that 44% of their samples
Table 2 - The association between HIF-1a/VEGF-C expression and clinical variables (Ribeira˜o Preto, Brazil, 2010).
Variables HIF-1a expression (%) p VEGF-C expression (%) p
Negative Positive Negative Positive
Age (years) 0.06 0.79
,50 6 (60) 4 (40) 4 (40) 6 (60)
50+ 4 (20) 16 (80) 7 (35) 13 (65)
Tumor size (cm) 1.0 0.76
,5 4 (33.3) 8 (66.7) 4 (33.3) 8 (66.7)
5+ 6 (33.3) 12 (66.7) 7 (38.8) 11 (61.2)
Clinical staging (TNM) 0.56 0.74
II 2 (25) 6 (75) 4 (50) 4 (50)
III 8 (36.4) 14 (63.6) 7 (31.8) 15 (68.2)
Histological grade* 0.18 0.68
I 0 (0) 3 (100) 1 (33.3) 2 (66.7)
II 8 (50) 8 (50) 7 (43.8) 9 (56.2)
III 2 (18.2) 9 (81.8) 3 (27.3) 8 (72.7)
Menopausal status 0.07 0.91
Menopause 3 (18.7) 13 (81.3) 6 (37.5) 10 (62.5)
Pre-menopause 7 (50) 7 (50) 5 (35.7) 9 (64.3)
Clinical response 0.10 0.46
Complete 2 (15.4) 11 (84.6) 4 (30.8) 9 (69.2)
Incomplete/no response 5 (45.5) 6 (54.5) 5 (45.5) 6 (54.5)
Pathological response 0.10 0.04
Complete 0 (0) 6 (100) 0 (0) 6 (100)
Incomplete/no response 5 (33.3) 10 (66.7) 7 (46.6) 8 (53.4)
Axillary status 0.02 0.70
Positive 8 (53.3) 7 (46.7) 5 (33.3) 10 (66.7)
Negative 2 (13.3) 13 (86.7) 6 (40) 9 (60)
ER 0.59 0.98
Positive 7 (36.8) 12 (63.2) 7 (36.8) 12 (63.2)
Negative 3 (27.3) 8 (72.7) 4 (36.4) 7 (63.6)
PR 0.30 0.92
Positive 6 (42.9) 8 (57.1) 5 (35.7) 9 (64.3)
Negative 4 (25) 12 (75) 6 (37.5) 10 (62.5)
c-erbB-2 0.78 0.79
Positive 3 (30) 7 (70) 7 (35) 13 (65)
Negative 7 (35) 13 (65) 4 (40) 6 (60)
Total 10 (33.3) 20 (66.7) 11 (36.3) 19 (63.3)
*The second and third histological grades were clustered into one category for the Fisher’s test.
A B
Figure 1 - The presence (a) and absence (b) of HIF-1a expression in breast cancer cells (DAB antibody, 200x).
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were positive for HIF-1a, and 13.5% of HIF-1a was
distributed perinecrotically. By contrast, 30.5% of HIF-1a
had a more diffuse expression, which was indicative of
alternative activation (of p53 mutation or HER-2 over-
expression, for example). The effect of HER-2 on HIF-1a
activation has been determined by identifying significant
associations (with the expression of the c-erbB-2 antigen)
and has been demonstrated using plasma analyses on
locally advanced tumors conducted by our institution.16
Moreover, the effect of HER-2 on HIF-1a activation has been
extensively described.10, 15, 22, 24 However, in the present
study, an association between HER-2 and HIF-1a activation
was not observed due to limited sampling.
The expression level of VEGF-C (63.3%) in the present
investigation was similar to the results obtained in previous
studies15, 26-28 on breast ductal carcinomas. In our study,
staining was localized to the cytoplasm, which is in
accordance with the results of previous studies.29
Although VEGF-C expression could not be correlated with
clinical parameters (except for complete pathological
response), angiogenesis is extremely important for tumor
growth. The level of VEGF-C expression was expected to be
reduced, leading to rapid cell apoptosis. Singh et al.27
observed reduced levels of VEGF expression in the tissues
of patients who displayed excellent clinical responses after
NACT.
A significant association between positive axillary status
and strong/diffuse HIF-1a staining was observed in locally
advanced tumors. This finding is in accordance with the
results of a previous study conducted by Gruber et al., who
evaluated 77 patients.23 In the abovementioned investiga-
tion, HIF-1a was expressed in the majority of patients with
positive axilla and served as a poor prognostic factor,
especially for T1/T2 tumors. In particular, upon association
with HIF-1a, no variables had significant association in the
multivariate analysis. Schindl and colleagues14 obtained
similar results in patients with positive axilla or T1/T2
tumors (192/206 patients) and demonstrated that HIF-1a
expression was highly significant. Moreover, Schoppmann
et al.30 found a significant association between HIF-1a
expression and the amount of peritumoral lymphangiogen-
esis in breast cancer patients.
Similar to previous reports,15,23 a significant association
between HIF-1a and large tumors and more advanced
clinical staging was not observed in the present study.
Conversely, Kronblad et al.24 observed a significant positive
correlation, especially in tumors with diameters greater than
5 centimeters. However, this association did not remain
after multivariate analysis. Logistic regression could not be
performed in our study due to limited sampling.
Nevertheless, we concur with Gruber’s hypothesis,23 which
states that the impact of HIF-1a is minimized in more
advanced tumors due to repression by adaptive mechan-
isms.
Bos et al.15 conducted a study on 81 negative axilla and 69
positive axilla patients and concluded that high HIF-1a
levels had a profound impact on the overall survival and
disease-free survival of patients with negative axilla.
Alternatively, high HIF-1a levels did not have an effect on
positive axillary patients. In the abovementioned study,
patients did not receive NACT because all locally advanced
tumors were excluded; however, NACT would likely affect
patients in more advanced stages.
Tumor volume has been associated with a determined
factor. For example, larger breast tumors are positively
related to VEGF levels.22 Furstenberger et al.31 analyzed
patients in diverse clinical stages and found that the VEGF
values of subjects in the control group and patients with
tumors were 92 pg/ml and 132 pg/ml, respectively.
However, Marana et al.16 did not observe any significant
relationship between tumor volume and plasmatic VEGF
level (p= 0.736). This result may be attributed to the
occurrence of locally advanced breast cancers, not to the
presence of tumors with different sizes. Similar results were
observed in the present study.
Histological grade was not associated with HIF-1a, even
when this variable was divided into low and high grades.
This result may be attributed to the sample used in the
current investigation, which was different from that of other
studies.15, 24 Another possibility is that the patients in our
sample had a high percentage of positive lymph nodes
(50%). This result could also explain the results obtained
from previous studies conducted on patients with positive
axillary status.14,23 However, Kronblad et al.24 evaluated 564
A B
Figure 2 - The presence (a) and absence (b) of VEGF-C expression in breast cancer cells (Anti-VEGF-C antibody mouse isotype IgG2b,k,
200x).
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patients and observed a positive correlation between higher
histological grade and HIF-1a expression (p= 0.003).
In the present study, age less than 50 years and
premenopausal status were slightly associated with
increased HIF-1a expression; however, the crude odds ratio
did not corroborate this association, which is similar to the
results of previous studies.15, 23 A similar correlation with
VEGF was not observed.
HIF-1a expression did not have an effect on the clinical
and pathological responses of patients who underwent
NACT; thus, HIF-1a is not a predictive factor. Few studies
aiming to establish a predictive value of HIF-1a in
neoadjuvant treatments have been conducted; however,
further investigations would stimulate research on targeted
therapies.
Neither a positive nor a negative association between
HIF-1a expression and the estrogen receptor concentration
was observed in the present study. The expression of
estrogen receptors in mammary cancer cells is reduced
under hypoxic conditions (MCF-7 and CAMA-1). The
observed reduction in protein production in these cells
and the oxygen level are directly related.10 Compared to
normoxic conditions, tamoxifen response in breast cancer
cells of premenopausal patients is reduced under hypoxic
conditions.32 Thus, proteosomic degradation occurs at these
receptors, reducing the concentration of activated forms.
Interestingly, Generali et al.33 found that HIF-1-a was an
independent predictor of poor response, especially in ER-
positive patients.
Similar to the results obtained from other authors, VEGF
expression was not correlated with ER and PR status in the
present study;27 however, VEGF production in breast cancer
cells was stimulated by estrogen and progestin. Foekens
et al.29 studied breast cancer cell lines and suggested that
this discrepancy might be due to the constitutive expression
of high levels of VEGF by ER-negative breast cancer cells.
Alternatively, the expression of VEGF is well-controlled in
better-differentiated ER-positive breast cancer cells.
The expression of c-erbB-2 antigen in patients with HIF-
1a expression has been well documented. Giatromanolaki
et al.34 showed that patients with high HIF-1a expression
and HER-2 overexpression had a lower overall survival rate.
In our study, no correlation with HIF-1a or VEGF-C
expression was observed. Assuming that HER2/neu protein
expression could affect cell migration and proliferation, as
well as the spread of lymphangiogenic tumors via VEGF-C
upregulation, Schoppmann et al.35 demonstrated that
HER2/neu expression was related to significantly stronger
VEGF-C expression and lymphangiogenesis in lymph node-
positive breast cancer patients.
The results of the present study emphasized the role of
HIF-1a as a poor prognostic factor and demonstrated that
increased levels of this protein are associated with positive
axillary lymph nodes. A connection between the expression
of hallmarks related to hypoxia and poor outcomes was also
observed, which reinforces the need for studies concerning
the role of HIF-1a as a predictive factor, the creation of new
HIF-1a inhibitors and their genic products, the identification
of a subpopulation of patients who will benefit from this
therapy (especially previously treated patients), and the
attainment of knowledge about a hallmark that may be used
in targeted therapies. The VEGF-C expression results
obtained in the present investigation were in accordance
with those of previous studies. In particular, VEGF-C
expression was higher in patients with complete pathologi-
cal response, which confirms its ability to act as a predictive
factor.
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